Current Psychiatry Reports

, Volume 8, Issue 5, pp 345–354 | Cite as

Management of methamphetamine abuse and dependence

  • Walter Ling
  • Richard Rawson
  • Steve Shoptaw


Preliminary implications for evidence-based treatments and future practice may be drawn from new research findings that inspire a fresh view of methamphetamine dependence and associated medical consequences. Current user populations include increasingly impacted subgroups (ie, youths, women, men who have sex with men, and rural residents); complex consequences of methamphetamine abuse among these subgroups require additional efforts involving contextual understanding of characteristics and needs to develop effective treatments. The neurobiological data on cellular activity of methamphetamine taken with findings from neuroimaging studies indicate potential targets for pharmacologic interventions. In early trials, several candidate medications—bupropion, modafinil, and, to a lesser extent, baclofen—have shown promise in treating aspects of methamphetamine dependence, including aiding memory function necessary to more effectively participate in and benefit from behavioral therapies. Clinicians and researchers must interact to efficiently address the problems of methamphetamine dependence, a major drug problem in the United States and the world.


Cocaine Methamphetamine Bupropion Baclofen Methamphetamine User 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    World Health Organization (WHO): Amphetamine-type stimulants: a report from the WHO meeting on amphetamines, MDMA and other psychostimulants. Geneva: WHO; 1997.Google Scholar
  2. 2.
    Evans E, Longshore D: Evaluation of the substance abuse and crime prevention act: treatment clients and program types during the first year of implementation. J Psychoactive Drugs 2004, May(Suppl 2):165–174.Google Scholar
  3. 3.
    Longshore D, Urada D, Hser Y-I, Anglin MD: California’s Proposition 36 evaluation. Paper presented by Richard Rawson at Join Together Public Hearing. Santa Fe, NM; January 30, 2006.Google Scholar
  4. 4.
    Office of Applied Studies, National Survey on Drug Use and Health, 2003 and 2004. SAMHSA, Table 1.14A Types of illicit drug use in lifetime, past year, and past month; numbers in thousands, 2003 and 2004. Available at: http://oas. htm#tab1.14a. Accessed May 2006.Google Scholar
  5. 5.
    Shoptaw S, Reback CJ, Peck JA, et al.: Behavioral treatment approaches for methamphetamine dependence and HIVrelated sexual risk behaviors among urban gay and bisexual men. Drug Alcohol Depend 2005, 78:125–134. This trial examined behavioral therapies delivered to 162 methamphetamine-dependent gay and bisexual men (GBM). Improved overall outcomes persisted at 1 year, showing that methamphetamine-dependent GBM do reduce drug use and HIV-risky sexual behaviors in response to behavioral drug abuse treatments such as CM and CBT, especially those tailored to needs and characteristics of GBM.PubMedCrossRefGoogle Scholar
  6. 6.
    California Alcohol and Drug Programs. Prop 36 Evaluation Report. Available at: http://www.adp.cahwnet. gov/director/PDF/Haight%20Ashbury_6-11-05.pdf. Accessed July 24, 2006.Google Scholar
  7. 7.
    Johnston LD, O’Malley PM, Bachman JG, Schulenberg JE: Monitoring the Future National Results on Adolescent Drug Use: Overview of Key Findings. Bethesda, MD: National Institute on Drug Abuse; 2005. [NIH publication no. 06-5882.]Google Scholar
  8. 8.
    United Nations Office on Drugs and Crime. World Drug Report 2005. Available at: world_drug_report.html. Accessed May 2006.Google Scholar
  9. 9.
    McIver C, Pointer S, Ali R, et al.: Functional Use of Amphetamine-Type Stimulants Amongst High-Risk Occupational Groups in China, Nigeria, Philippines and Thailand. A Report From the WHO Collaborative Study on Amphetamine-Type Stimulants. Geneva: WHO; 2002. [DASSA monograph no. 18.]Google Scholar
  10. 10.
    Farrell M, Marsden J, Ali R, Ling W: Methamphetamine: Drug use and psychoses becomes a major public health issue in the Asia Pacific region. Addiction 2002, 97:771–772.PubMedCrossRefGoogle Scholar
  11. 11.
    Hanson GR, Sandoval V, Riddle E, Fleckenstein AE: Psychostimulants and vesicle trafficking: a novel mechanism and therapeutic implications. Ann N Y Acad Sci 2004, 1025:146–150.PubMedCrossRefGoogle Scholar
  12. 12.
    Pierce R, Kumaresan V: The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse? Neurosci Biobehav Rev 2006, 30:215–238.PubMedCrossRefGoogle Scholar
  13. 13.
    Sandoval V, Riddle EL, Hanson GR, Fleckenstein AE: Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits. J Pharmacol Exp Ther 2003, 304:1181–1187.PubMedCrossRefGoogle Scholar
  14. 14.
    Jernigan T, Gamst A, Archibald S, et al.: Effects of methamphetamine dependence and HIV infection on cerebral morphology. Am J Psychiatry 2005, 162:1461–1472. Investigation via MRI showed that methamphetamine dependence was associated with increased basal ganglia and parietal cortex volume, with a greater effect in the nucleus accumbens seen among younger individuals. Brain insults from methamphetamine appear to be compounded in range by HIV infection.PubMedCrossRefGoogle Scholar
  15. 15.
    Iyo M, Sekine Y, Mori N: Neuromechanism of developing methamphetamine psychosis: a neuroimaging study. Ann N Y Acad Sci 2004, 1025:288–295.PubMedCrossRefGoogle Scholar
  16. 16.
    London E, Berman S, Voytek B, et al.: Cerebral metabolic dysfunction and impaired vigilance in recently abstinent methamphetamine abusers. Biol Psychiatry 2005, 58:770–778.PubMedCrossRefGoogle Scholar
  17. 17.
    Newton TF, Kalechstein AD, Hardy DJ, et al.: Association between quantitative EEG and neurocognition in methamphetamine-dependent volunteers. Clin Neurophysiol 2004, 115:194–198.PubMedCrossRefGoogle Scholar
  18. 18.
    McKetin R, Mattick RP: Attention and memory in illicit amphetamine users: comparison with non-drug-using controls. Drug Alcohol Depend 1998, 50:181–184.PubMedCrossRefGoogle Scholar
  19. 19.
    Monterosso JR, Aron AR, Cordova X, et al.: Deficits in response inhibition associated with chronic methamphetamine abuse. Drug Alcohol Depend 2005, 79:273–277. Cerebral deficits involving frontal/basal ganglia regions that are important for inhibitory control are associated with methamphetamine dependence.PubMedCrossRefGoogle Scholar
  20. 20.
    Semple SJ, Zians J, Grant I, Patterson TL: Impulsivity and methamphetamine use. J Subst Abuse Treat 2005, 29:85–93.PubMedCrossRefGoogle Scholar
  21. 21.
    Simons JS, Oliver MN, Gaher RM, et al.: Methamphetamine and alcohol abuse and dependence symptoms: associations with affect lability and impulsivity in a rural treatment population. Addict Behav 2005, 30:1370–1381.PubMedCrossRefGoogle Scholar
  22. 22.
    Paulus MP, Tapert SF, Schuckit MA: Neural activation patterns of methamphetamine-dependent subjects during decision making predict relapse. Arch Gen Psychiatry 2005, 62:761–768.PubMedCrossRefGoogle Scholar
  23. 23.
    Rogers RD, Everitt BJ, Baldacchino A, et al.: Dissociable deficits in the decision-making cognition of chronic amphetamine abusers, opiate abusers, patients with focal damage to prefrontal cortex, and tryptophan-depleted normal volunteers: evidence for monoaminergic mechanism. Neuropsychopharmacology 1999, 20:322–339.PubMedCrossRefGoogle Scholar
  24. 24.
    Turner DC, Clark L, Pomarol-Clotet E, et al.: Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology 2004, 29:1363–1373.PubMedCrossRefGoogle Scholar
  25. 25.
    Villeneuve E, Lemelin S: Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target. J Clin Psychiatry 2005, 66:1298–1303.PubMedGoogle Scholar
  26. 26.
    Ressler K, Rothbaum B, Tannenbaum L, et al.: Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 2004, 61:1136–1144.PubMedCrossRefGoogle Scholar
  27. 27.
    Alkon DL, Epstein H, Kuzirian A, et al.: Protein synthesis required for long-term memory is induced by PKC activation on days before associative learning. Proc Natl Acad Sci U S A 2005, 102:16432–16437.PubMedCrossRefGoogle Scholar
  28. 28.
    SAMHSA Office of Applied Studies. Drug Abuse Warning Network, 2004: National Estimates of Drug-Related Emergency Department Visits. Available at: https://dawninfo. Accessed May 2006.Google Scholar
  29. 29.
    Richards JR, Derlet RW, Duncan DR: Chemical restraint for the agitated patient in the emergency department: lorazepam versus droperidol. J Emerg Med 1998, 16:567–573.PubMedCrossRefGoogle Scholar
  30. 30.
    Battaglia J, Moss S, Rush J, et al.: Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med 1997, 15:335–340.PubMedCrossRefGoogle Scholar
  31. 31.
    Battaglia J: Pharmacological management of acute agitation. Drugs 2005, 65:1207–1222.PubMedCrossRefGoogle Scholar
  32. 32.
    Daniels JR, Wessinger WD, Hardwick WC, et al.: Effects of anti-phencyclidine and anti-(+)-methamphetamine monoclonal antibodies alone and in combination on the discrimination of phencyclidine and (+)-methamphetamine by pigeons. Psychopharmacology berl 2006, 185:36–44.PubMedCrossRefGoogle Scholar
  33. 33.
    Laurenzana EM, Byrnes-Blake KA, Milesi-Halle A, et al.: Use of anti-(+)-methamphetamine monoclonal antibody to significantly alter (+)-methamphetamine and (+)-amphetamine disposition in rats. Drug Metab Dispos 2003, 31:1320–1326.PubMedCrossRefGoogle Scholar
  34. 34.
    McGregor C, Srisurapanont M, Jittiwutikarn J, et al.: The nature, time course and severity of methamphetamine withdrawal. Addiction 2005, 100:1320–1329.PubMedCrossRefGoogle Scholar
  35. 35.
    Newton TF, Roache JD, De La Garza R, et al.: Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology 2006, 31:1537–1544.PubMedCrossRefGoogle Scholar
  36. 36.
    Rawson R, Gonzales R, Ling W: Methamphetamine abuse and dependence: an update [lesson]. Dir Psychiatry 2006, In press.Google Scholar
  37. 37.
    Ujike H, Sato M: Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis. Ann N Y Acad Sci 2004, 1025:279–287.PubMedCrossRefGoogle Scholar
  38. 38.
    Ujike H, Harano M, Inada T, et al.: Nine-or fewer repeat alleles in VNTR polymorphism of the dopamine transporter gene is a strong risk factor for prolonged methamphetamine psychosis. Pharmacogenomics J 2003, 3:242–247.PubMedCrossRefGoogle Scholar
  39. 39.
    Curran C, Byrappa N, McBride A: Stimulant psychosis: systematic review. Br J Psychiatry 2004, 185:196–204.PubMedCrossRefGoogle Scholar
  40. 40.
    Cooper WO, Arbogast PG, Ding H, et al.: Trends in prescribing of antipsychotic medications for US children. Ambul Pediatr 2006, 6:79–83.PubMedCrossRefGoogle Scholar
  41. 41.
    Gotti C, Clementi F: Neuronal nicotinic receptors: from structure to pathology. Prog Neurobiol 2004, 74:363–396.PubMedCrossRefGoogle Scholar
  42. 42.
    Olfson M, Blanco C, Liu L, et al.: National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 2006, 63:679–685.PubMedCrossRefGoogle Scholar
  43. 43.
    Chen CK, Lin SK, Sham PC, et al.: Morbid risk for psychiatric disorder among the relatives of methamphetamine users with and without psychosis. Am J Med Genet B Neuropsychiatr Genet 2005, 136:87–91.PubMedGoogle Scholar
  44. 44.
    Rawson R, McCann M, Flammino F, et al.: A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals. Addiction 2006, 101:267–274.PubMedCrossRefGoogle Scholar
  45. 45.
    Rawson RA, Marinelli-Casey P, Anglin MD, et al.: A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence. Addiction 2004, 99:708–717.PubMedCrossRefGoogle Scholar
  46. 46.
    Elkashef A, Rawson R, Anderson A, et al.: Bupropion for the treatment of methamphetamine dependence. Paper presented at the 68th Annual Meeting of the College on Problems of Drug Dependence. Scottsdale, AZ; June 19, 2006. This placebo-controlled study examined bupropion as a treatment for methamphetamine dependence in 151 patients. Bupropion increasingly shows promise as a pharmacotherapy for preventing relapse from methamphetamine-dependent individuals, particularly in early abstinence in conjunction with behavioral therapy.Google Scholar
  47. 47.
    Roll JM, Petry NM, Stitzer M, et al.: Contingency management for the treatment for methamphetamine use disorders. Am J Psychiatry 2006, In press.Google Scholar
  48. 48.
    Grabowski J, Shearer J, Merrill J, Negus S: Agonist-like replacement pharmacotherapy for stimulant abuse and dependence. Addict Behav 2004, 29:1439–1464.PubMedCrossRefGoogle Scholar
  49. 49.
    Peck JA, Reback CJ, Yang X, et al.: Sustained reductions in drug use and depression symptoms from treatment for drug abuse in methamphetamine-dependent gay and bisexual men. J Urban Health 2005, 82(Suppl 1):i100-i108.PubMedGoogle Scholar
  50. 50.
    Randall DC, Shneerson JM, Plaha KK, File SE: Modafinil affects mood, but not cognitive function, in healthy young volunteers. Hum Psychopharmacol 2003, 18:163–173.PubMedCrossRefGoogle Scholar
  51. 51.
    Rabkin JG, McElhiney MC, Rabkin R, Ferrando SJ: Modafinil treatment for fatigue in HIV+ patients: a pilot study. J Clin Psychiatry 2004, 65:1688–1695.PubMedCrossRefGoogle Scholar
  52. 52.
    Turner DC, Clark I, Dowson J, et al.: Modafinil improves cognition and response inhibition in adult attention-deficit/ hyperactivity disorder. Biol Psychiatry 2004, 55:1031–1040.PubMedCrossRefGoogle Scholar
  53. 53.
    Reback CJ, Larkins S, Shoptaw S: Changes in the meaning of sexual risk behaviors among gay and bisexual male methamphetamine abusers before and after drug treatment. AIDS Behav 2004, 8:87–98.PubMedCrossRefGoogle Scholar
  54. 54.
    Heinzerling KG, Shoptaw S, Peck JA, et al.: Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence. Drug Alcohol Depend 2006 [Epub ahead of print]. This double-blind trial tested effects of baclofen and gabapentin (baclofen n = 25, gabapentin n = 26, placebo n = 37) for treatment of methamphetamine abusers. Baclofen but not gabapentin showed positive effects on outcomes.Google Scholar
  55. 55.
    Martell BA, Mitchell E, Poling J, et al.: Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry 2005, 58:158–164.PubMedCrossRefGoogle Scholar
  56. 56.
    deCharms RC, Maeda F, Glover GH, et al.: Control over brain activation and pain learned by using real-time functional MRI. Proc Natl Acad Sci U S A 2005, 102:18626–18631.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  1. 1.UCLA Integrated Substance Abuse Programs, David Geffen School of Medicine at UCLALos AngelesUSA

Personalised recommendations